JPWO2020264172A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020264172A5 JPWO2020264172A5 JP2021576251A JP2021576251A JPWO2020264172A5 JP WO2020264172 A5 JPWO2020264172 A5 JP WO2020264172A5 JP 2021576251 A JP2021576251 A JP 2021576251A JP 2021576251 A JP2021576251 A JP 2021576251A JP WO2020264172 A5 JPWO2020264172 A5 JP WO2020264172A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- moieties
- compound according
- pharmaceutically acceptable
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
均等物
主題発明のある実施形態が議論されてきたが、上記の明細書は例示的なものであり、限定的なものではない。本明細書および以下の特許請求の範囲を検討すると、本発明の多くの変形が当業者に明らかになるであろう。本発明の全範囲は、特許請求の範囲、その均等物の全範囲、および明細書、ならびにそのような変形を参照することによって決定されるべきである。
本発明は以下の実施形態を含む。
[1]
式Iもしくは式IIの化合物:
Xは、結合、アリール、またはヘテロアリールであり;
Lは、1~35個の炭素原子を含むアルキレン、アルケニレンまたはアルキニレン鎖であり、任意選択で:
少なくとも1個であるが10個以下のLの-CH
2
-部分は、独立して、-C(=O)-、-C(=O)-NR
3
--NR
3
-C(=O)-、-C(=O)-O-、-O-C(=O)-、-NR
3
-C(=O)-NR
3
-、-O-C(=O)-NR
3
-、-NR
3
-C(=O)-O-、-O-、-S-、および-NR
3
-から選択される部分で置換されており、
ただし、Lの-CH
2
-部分の数が、Lの
-C(=O)-、-C(=O)-NR
3
--NR
3
-C(=O)-、-C(=O)-O-、-O-C(=O)-、-NR
3
-C(=O)-NR
3
-、
-O-C(=O)-NR
3
-、-NR
3
-C(=O)-O-、-O-、-S-、および-NR
3
-部分の集合数よりも多く、
ただし、Lの各-C(=O)-、-C(=O)-NR
3
--NR
3
-C(=O)-、
-C(=O)-O-、-O-C(=O)-、-NR
3
-C(=O)-NR
3
-、-O-C(=O)-NR
3
-、-NR
3
-C(=O)-O-、-O-、-S-、および-NR
3
-部分の間に少なくとも1個の-CH
2
-が存在し;
Z-Lは、-CH
2
-L、-O-CH
2
-L、または-NR
3
-CH
2
-Lであり;および
R
1
、R
2
、およびR
3
は、それぞれ独立して、Hおよびアルキルから選択される]
またはその薬学的に許容され得る塩。
[2]
前記化合物が式Ia、Ib、IIa、またはIIb:
[3]
Xがフェニルまたはピリジルである、[1]または[2]に記載の化合物。
[4]
Xがフェニルである、[3]に記載の化合物。
[5]
Xがピリジルである、[3]に記載の化合物。
[6]
Xが結合である、[1]または[2]に記載の化合物。
[7]
Z-Lが-NH-CH
2
-Lである、[1]~[6]のいずれか一項に記載の化合物。
[8]
Z-Lが-O-CH
2
-Lである、[1]~[6]のいずれか一項に記載の化合物。
[9]
Lが2~25個の炭素原子を含む、[1]~[8]のいずれか一項に記載の化合物。
[10]
Lが2個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[11]
Lが3個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[12]
Lが4個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[13]
Lが5個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[14]
Lが6個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[15]
Lが7個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[16]
Lが8個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[17]
Lが9個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[18]
Lが10個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[19]
Lが11個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[20]
Lが12個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[21]
Lが13個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[22]
Lが14個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[23]
Lが15個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[24]
Lが16個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[25]
Lが17個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[26]
Lが18個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[27]
Lが19個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[28]
Lが20個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[29]
Lが21個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[30]
Lが22個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[31]
Lが23個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[32]
Lが24個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[33]
Lが25個の炭素原子を含む、[1]~[9]のいずれか一項に記載の化合物。
[34]
少なくとも1個であるが5個以下である、Lの-CH
2
-部分はアミド部分で置換されている(例えば、
[35]
Lの少なくとも1個の-CH
2
-部分がアミド部分で置換されている(例えば、
[36]
Lの少なくとも2個の-CH
2
-部分が2個のアミド部分で置換されている(例えば、
[37]
Lの少なくとも3個の-CH
2
-部分が3個のアミド部分で置換されている(例えば、
[38]
Lの1、2、3、または6個の-CH
2
-部分が1、2、3、または6個のアミド部分で置換されている(例えば、
[39]
前記アミド部分が少なくとも1個の炭素原子(例えば、CH
2
単位)によって分離されている、[34]~[38]のいずれか一項に記載の化合物。
[40]
前記アミド部分が少なくとも6個の炭素原子(例えば、CH
2
単位)によって分離されている、[39]に記載の化合物。
[41]
前記アミドの炭素原子(例えば、C(=O)単位)がZに結合している、[34]~[40]のいずれか一項に記載の化合物。
[42]
Lの炭素原子がZに結合している、[1]~[41]のいずれか一項に記載の化合物。
[43]
少なくとも1個であるが10個以下である、Lの-CH
2
-部分が酸素原子で置換されている、[1]~[42]のいずれか一項に記載の化合物。
[44]
Lの少なくとも1個の-CH
2
-部分が-O-で置換されている、[1]~[43]のいずれか一項に記載の化合物。
[45]
Lの少なくとも2個の-CH
2
-部分が少なくとも2個の-O-で置換されている、[1]~[43]のいずれか一項に記載の化合物。
[46]
Lの少なくとも6個の-CH
2
-部分が少なくとも6個の-O-で置換されている、[1]~[43]のいずれか一項に記載の化合物。
[47]
Lの1、2、または6個の-CH
2
-部分が-O-で置換されている、[1]~[43]のいずれか一項に記載の化合物。
[48]
前記Lが、エチレングリコール部分、ジエチレングリコール部分、トリエチレングリコール部分、またはオリゴエチレングリコール部分を含む、[1]~[43]のいずれか一項に記載の化合物。
[49]
Lの少なくとも1個の-CH
2
-部分が-NR
3
-で置換されている、[1]~[48]のいずれか一項に記載の化合物。
[50]
R
3
がHである、[49]に記載の化合物。
[51]
Lの少なくとも1個の-CH
2
-部分が-C(=O)-で置換されている、[1]~[50]のいずれか一項に記載の化合物。
[52]
またはその薬学的に許容され得る塩。
[53]
先行する請求項のいずれか一項に記載の化合物および薬学的に許容され得る担体を含む医薬組成物。
[54]
細胞を、[1]~[52]のいずれか一項に記載の化合物またはその薬学的に許容され得る塩と接触させることを含む、SMARCA2またはSMARCA4を分解する方法。
[55]
疾患または障害の治療を必要とする対象に、[1]~[52]のいずれか一項に記載の化合物を投与することを含む、疾患または障害を治療する方法。
[56]
SMARCA2またはSMARCA4の分解が有効である疾患または障害の治療を必要とする対象に、[1]~[52]のいずれか一項に記載の化合物を投与することを含む、SMARCA2またはSMARCA4の分解が有効である疾患または障害を治療する方法。
[57]
前記疾患または障害はSMARCA2の分解が有効である、[56]に記載の方法。
[58]
前記疾患または障害はSMARCA4の分解が有効である、[56]に記載の方法。
[59]
前記疾患または障害は癌である、[55]~[58]のいずれか一項に記載の方法。
[60]
前記癌は、滑膜肉腫、肺癌、卵巣癌、脳癌、腎臓癌、白血病、非小細胞肺癌、バーキットリンパ腫、小児髄芽腫、膵臓腺癌、卵巣明細胞癌、腎細胞癌、子宮内膜癌および黒色腫から選択される、[59]に記載の方法。
[61]
前記方法が、1つまたは複数の追加の化学療法剤を併用投与することをさらに含む、[55]~[60]のいずれか一項に記載の方法。
Equivalents While certain embodiments of the subject invention have been discussed, the above specification is illustrative, not limiting. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, their full scope of equivalents, and the specification, along with such variations.
The present invention includes the following embodiments .
[1]
Compounds of Formula I or Formula II:
X is a bond, aryl, or heteroaryl;
L is an alkylene, alkenylene or alkynylene chain containing 1-35 carbon atoms, optionally:
at least one but no more than 10 —CH 2 — moieties of L are independently —C(=O)—, —C(=O)—NR 3 —NR 3 —C(=O) -, -C(=O)-O-, -OC(=O)-, -NR 3 -C(=O)-NR 3 -, -OC(=O)-NR 3 -, - substituted with a moiety selected from NR 3 —C(=O)—O—, —O—, —S—, and —NR 3 —;
provided that the number of —CH 2 — moieties of L is
-C(=O)-, -C(=O)-NR 3 --NR 3 -C(=O)-, -C(=O)-O-, -OC(=O)-,- NR 3 -C(=O)-NR 3 -,
-OC(=O)-NR 3 -, -NR 3 -C(=O)-O-, -O-, -S-, and -NR 3 - greater than the number of sets of moieties;
provided that each of L -C(=O)-, -C(=O)-NR 3 --NR 3 -C(=O)-,
-C(=O)-O-, -OC(=O)-, -NR 3 -C(=O)-NR 3 -, -OC(=O)-NR 3 -, -NR 3 at least one -CH 2 - is present between the -C(=O)-O-, -O-, -S-, and -NR 3 - moieties;
ZL is -CH 2 -L, -O-CH 2 -L, or -NR 3 -CH 2 -L; and
R 1 , R 2 and R 3 are each independently selected from H and alkyl]
or a pharmaceutically acceptable salt thereof.
[2]
wherein said compound is of Formula Ia, Ib, IIa, or IIb:
[3]
The compound of [1] or [2], wherein X is phenyl or pyridyl.
[4]
The compound of [3], wherein X is phenyl.
[5]
The compound of [3], wherein X is pyridyl.
[6]
The compound of [1] or [2], wherein X is a bond.
[7]
The compound according to any one of [1] to [6], wherein ZL is -NH-CH 2 -L.
[8]
The compound according to any one of [1] to [6], wherein ZL is -O-CH 2 -L.
[9]
The compound of any one of [1]-[8], wherein L contains 2-25 carbon atoms.
[10]
The compound of any one of [1]-[9], wherein L contains 2 carbon atoms.
[11]
The compound of any one of [1]-[9], wherein L contains 3 carbon atoms.
[12]
The compound of any one of [1]-[9], wherein L contains 4 carbon atoms.
[13]
The compound of any one of [1]-[9], wherein L contains 5 carbon atoms.
[14]
The compound of any one of [1]-[9], wherein L contains 6 carbon atoms.
[15]
The compound of any one of [1]-[9], wherein L contains 7 carbon atoms.
[16]
The compound of any one of [1]-[9], wherein L contains 8 carbon atoms.
[17]
The compound of any one of [1]-[9], wherein L contains 9 carbon atoms.
[18]
The compound of any one of [1]-[9], wherein L contains 10 carbon atoms.
[19]
The compound of any one of [1]-[9], wherein L contains 11 carbon atoms.
[20]
The compound of any one of [1]-[9], wherein L contains 12 carbon atoms.
[21]
The compound of any one of [1]-[9], wherein L contains 13 carbon atoms.
[22]
The compound of any one of [1]-[9], wherein L contains 14 carbon atoms.
[23]
The compound of any one of [1]-[9], wherein L contains 15 carbon atoms.
[24]
The compound of any one of [1]-[9], wherein L contains 16 carbon atoms.
[25]
The compound of any one of [1]-[9], wherein L contains 17 carbon atoms.
[26]
The compound of any one of [1]-[9], wherein L contains 18 carbon atoms.
[27]
The compound of any one of [1]-[9], wherein L contains 19 carbon atoms.
[28]
The compound of any one of [1]-[9], wherein L contains 20 carbon atoms.
[29]
The compound of any one of [1]-[9], wherein L contains 21 carbon atoms.
[30]
The compound of any one of [1]-[9], wherein L contains 22 carbon atoms.
[31]
The compound of any one of [1]-[9], wherein L contains 23 carbon atoms.
[32]
The compound of any one of [1]-[9], wherein L contains 24 carbon atoms.
[33]
The compound of any one of [1]-[9], wherein L contains 25 carbon atoms.
[34]
At least one, but no more than five —CH 2 — moieties of L are substituted with amide moieties (e.g.
[35]
At least one —CH 2 — moiety of L is replaced with an amide moiety (e.g.,
[36]
At least two —CH 2 — moieties of L are substituted with two amide moieties (eg,
[37]
At least three —CH 2 — moieties of L are substituted with three amide moieties (e.g.
[38]
1, 2, 3, or 6 —CH 2 — moieties of L are replaced with 1, 2, 3, or 6 amide moieties (e.g.,
[39]
The compound of any one of [34]-[38], wherein said amide moieties are separated by at least one carbon atom (eg, a CH 2 unit).
[40]
The compound of [39], wherein said amide moieties are separated by at least 6 carbon atoms (eg, CH2 units ).
[41]
The compound of any one of [34]-[40], wherein a carbon atom (eg, a C(=O) unit) of said amide is attached to Z.
[42]
The compound of any one of [1]-[41], wherein the carbon atom of L is attached to Z.
[43]
The compound according to any one of [1] to [42], wherein at least one, but no more than 10 —CH 2 — moieties of L are substituted with oxygen atoms.
[44]
The compound of any one of [1]-[43], wherein at least one -CH 2 - moiety of L is substituted with -O-.
[45]
The compound of any one of [1] to [43], wherein at least two —CH 2 — moieties of L are substituted with at least two —O—.
[46]
The compound of any one of [1] to [43], wherein at least 6 -CH 2 - moieties of L are substituted with at least 6 -O-.
[47]
The compound of any one of [1] to [43], wherein 1, 2, or 6 —CH 2 — moieties of L are replaced with —O—.
[48]
The compound of any one of [1]-[43], wherein said L comprises an ethylene glycol moiety, a diethylene glycol moiety, a triethylene glycol moiety, or an oligoethylene glycol moiety.
[49]
The compound of any one of [1]-[48], wherein at least one -CH 2 - moiety of L is substituted with -NR 3 - .
[50]
The compound of [49], wherein R3 is H.
[51]
The compound of any one of [1]-[50], wherein at least one -CH 2 - moiety of L is substituted with -C(=O)-.
[52]
or a pharmaceutically acceptable salt thereof.
[53]
A pharmaceutical composition comprising a compound according to any one of the preceding claims and a pharmaceutically acceptable carrier.
[54]
A method of degrading SMARCA2 or SMARCA4, comprising contacting a cell with the compound of any one of [1] to [52] or a pharmaceutically acceptable salt thereof.
[55]
A method of treating a disease or disorder comprising administering the compound of any one of [1] to [52] to a subject in need of treatment of the disease or disorder.
[56]
degradation of SMARCA2 or SMARCA4, comprising administering the compound of any one of [1] to [52] to a subject in need of treatment for a disease or disorder in which degradation of SMARCA2 or SMARCA4 is effective. A method of treating a disease or disorder that is efficacious.
[57]
The method of [56], wherein said disease or disorder is effected by degradation of SMARCA2.
[58]
The method of [56], wherein said disease or disorder is effected by degradation of SMARCA4.
[59]
The method of any one of [55]-[58], wherein said disease or disorder is cancer.
[60]
Said cancers include synovial sarcoma, lung cancer, ovarian cancer, brain cancer, renal cancer, leukemia, non-small cell lung cancer, Burkitt's lymphoma, pediatric medulloblastoma, pancreatic adenocarcinoma, ovarian clear cell carcinoma, renal cell carcinoma, intrauterine The method of [59], selected from membranous carcinoma and melanoma.
[61]
The method of any one of [55]-[60], wherein said method further comprises co-administering one or more additional chemotherapeutic agents.
Claims (15)
式中、
Xは、結合、アリール、またはヘテロアリールであり;
Lは、1~35個の炭素原子を含むアルキレン、アルケニレンまたはアルキニレン鎖であり、任意選択で、少なくとも1個であるが10個以下の、Lの-CH2-部分は、独立して、-C(=O)-、-C(=O)-NR3--NR3-C(=O)-、-C(=O)-O-、-O-C(=O)-、-NR3-C(=O)-NR3-、-O-C(=O)-NR3-、-NR3-C(=O)-O-、-O-、-S-、および-NR3-から選択される部分で置換されており、
ただし、Lの-CH2-部分の数が、Lの
-C(=O)-、-C(=O)-NR3--NR3-C(=O)-、-C(=O)-O-、-O-C(=O)-、-NR3-C(=O)-NR3-、-O-C(=O)-NR3-、-NR3-C(=O)-O-、-O-、-S-、および-NR3-部分の集合数よりも多く、
ただし、Lの各-C(=O)-、-C(=O)-NR3--NR3-C(=O)-、
-C(=O)-O-、-O-C(=O)-、-NR3-C(=O)-NR3-、-O-C(=O)-NR3-、-NR3-C(=O)-O-、-O-、-S-、および-NR3-部分の間に少なくとも1個の-CH2-が存在し;
Z-Lは、-CH2-L、-O-CH2-L、または-NR3-CH2-Lであり;および
R1、R2、およびR3は、それぞれ独立して、Hおよびアルキルから選択される、
化合物、またはその立体異性体もしくは薬学的に許容され得る塩。 Formula I or Formula II:
During the ceremony,
X is a bond, aryl, or heteroaryl;
L is an alkylene, alkenylene or alkynylene chain containing 1 to 35 carbon atoms, and optionally at least one but no more than 10 —CH 2 — moieties of L are independently — C(=O)-, -C(=O)-NR 3 --NR 3 -C(=O)-, -C(=O)-O-, -O-C(=O)-, -NR 3 -C(=O)-NR 3 -, -O-C(=O)-NR 3 -, -NR 3 -C(=O)-O-, -O-, -S-, and -NR 3 - is replaced by a portion selected from
provided that the number of -CH 2 - moieties of L is -C(=O)-, -C(=O)-NR 3 --NR 3 -C(=O)-, -C(=O) of L -O-, -OC(=O)-, -NR 3 -C(=O)-NR 3 -, -OC(=O)-NR 3 -, -NR 3 -C(=O) greater than the collective number of -O-, -O-, -S-, and -NR 3 - moieties;
provided that each of L -C(=O)-, -C(=O)-NR 3 --NR 3 -C(=O)-,
-C(=O)-O-, -OC(=O)-, -NR 3 -C(=O)-NR 3 -, -OC(=O)-NR 3 -, -NR 3 at least one -CH 2 - is present between the -C(=O)-O-, -O-, -S-, and -NR 3 - moieties;
ZL is -CH 2 -L, -O-CH 2 -L, or -NR 3 -CH 2 -L; and R 1 , R 2 , and R 3 are each independently H and selected from alkyl,
A compound, or a stereoisomer or pharmaceutically acceptable salt thereof.
任意選択で、前記アミド部分が少なくとも1個の炭素原子によって分離されているか、または、前記アミド部分が少なくとも6個の炭素原子によって分離されている、請求項1~5のいずれか1項に記載の化合物。 at least 1 but no more than 5 —CH 2 — moieties of L are substituted with amide moieties, or 1, 2, 3, or 6 —CH 2 — moieties of L are 1, substituted with 2, 3, or 6 amide moieties;
Optionally, the amide moieties are separated by at least one carbon atom, or the amide moieties are separated by at least 6 carbon atoms . compound.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867642P | 2019-06-27 | 2019-06-27 | |
US62/867,642 | 2019-06-27 | ||
PCT/US2020/039638 WO2020264172A1 (en) | 2019-06-27 | 2020-06-25 | Compounds, compositions, and methods for protein degradation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022538074A JP2022538074A (en) | 2022-08-31 |
JPWO2020264172A5 true JPWO2020264172A5 (en) | 2023-07-03 |
Family
ID=74062022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021576251A Pending JP2022538074A (en) | 2019-06-27 | 2020-06-25 | Compounds, compositions and methods for protein degradation |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220389023A1 (en) |
EP (1) | EP3989967A4 (en) |
JP (1) | JP2022538074A (en) |
CN (1) | CN114390924A (en) |
AU (1) | AU2020303575A1 (en) |
CA (1) | CA3144062A1 (en) |
WO (1) | WO2020264172A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230167081A1 (en) * | 2020-04-30 | 2023-06-01 | President And Fellows Of Harvard College | 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders |
WO2023004283A1 (en) * | 2021-07-19 | 2023-01-26 | Dana-Farber Cancer Institute, Inc. | Targeting dot1l and smarca4/2 for the treatment of mllr leukemia |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
US20180147202A1 (en) * | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
WO2017007612A1 (en) * | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
CN109562107A (en) * | 2016-05-10 | 2019-04-02 | C4医药公司 | Heterocycle degron body for target protein degradation |
CN109790143A (en) * | 2016-05-10 | 2019-05-21 | C4医药公司 | The C of amine connection for target protein degradation3Glutarimide degron body |
MA45502A (en) * | 2016-06-21 | 2019-04-24 | Janssen Biotech Inc | GENERATION OF FUNCTIONAL BETA CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS WITH GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE |
KR20190140438A (en) * | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | Inhibition of SMARCA2 for Cancer Treatment |
WO2019055657A1 (en) * | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Baf complex modulating compounds and methods of using the same |
US20230072658A1 (en) * | 2019-06-10 | 2023-03-09 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
-
2020
- 2020-06-25 WO PCT/US2020/039638 patent/WO2020264172A1/en active Application Filing
- 2020-06-25 AU AU2020303575A patent/AU2020303575A1/en active Pending
- 2020-06-25 US US17/622,091 patent/US20220389023A1/en active Pending
- 2020-06-25 CN CN202080045776.9A patent/CN114390924A/en active Pending
- 2020-06-25 JP JP2021576251A patent/JP2022538074A/en active Pending
- 2020-06-25 CA CA3144062A patent/CA3144062A1/en active Pending
- 2020-06-25 EP EP20833332.8A patent/EP3989967A4/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004264421B2 (en) | Platinum complexes for the treatment of tumors | |
JP2020007311A5 (en) | ||
US5916896A (en) | Water-soluble esters of camptothecin compounds | |
WO2021218110A1 (en) | Benzothiazolyl biaryl compound, and preparation method and use | |
JPWO2021168193A5 (en) | ||
KR880006246A (en) | Rebeccamycin homologue | |
Mikata et al. | Intercalator-linked cisplatin: synthesis and antitumor activity of cis-dichloroplatinum (II) complexes connected to acridine and phenylquinolines by one methylene chain | |
RU2015126856A (en) | DISULPHIDIC MASKED MEDICINAL COMPOSITIONS AND METHODS | |
TWI755788B (en) | Toll-like receptor agonists | |
RU2006134024A (en) | TETRACYCLIC DERIVATIVES OF LACTAM AND THEIR USE | |
RU2016147654A (en) | CANCER TREATMENT COMPOUNDS | |
JPWO2020178282A5 (en) | ||
US6979738B2 (en) | Quadruplex stabilizer | |
WO2022169780A1 (en) | Selective bcl-xl protac compounds and methods of use | |
JPWO2020264172A5 (en) | ||
JPH0714877B2 (en) | Metalricenium salts and their use as cytostatics in the treatment of cancer | |
JP2008544985A (en) | Platinum complexes with mononitrile-containing ligands | |
US7977500B2 (en) | Platinum complexes for targeted drug delivery | |
JP5313895B2 (en) | Camptothecin derivatives having antitumor activity | |
CN1114605C (en) | Novel camptothecin derivatives | |
EP0864578A2 (en) | Platinum (IV) complex and pharmaceutical composition comprising the same | |
EP1618116B1 (en) | Ruthenium(ii) complexes for the treatment of tumors | |
KR900001654A (en) | Glycerin derivatives and their pharmacological uses | |
RU2785124C1 (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists | |
AU563319B2 (en) | Aziridino derivative of a cyclophosphazene compound |